PolyPid Ltd.
PYPDAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 27, 2026 | Oppenheimer | Lee Sulewski | $10.00(+89%) | $5.29 | TheFly |
| Jul 22, 2026 | Craig-Hallum | $12.00(+201%) | $3.98 | TheFly | |
| Jul 22, 2026 | H.C. Wainwright | Brandon Folkes | $13.00(+248%) | $3.74 | StreetInsider |
| Jun 17, 2025 | Roth Capital | Boobalan Pachaiyappan | $9.00(+155%) | $3.53 | TheFly |
| Nov 4, 2024 | Craig-Hallum | Chase Knickerbocker | $10.00(+200%) | $3.33 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Jul 21, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 11, 2026 |
| Roth Capital | maintain | Buy | Nov 13, 2025 |
| Craig-Hallum | maintain | Buy | Aug 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 13, 2025 |
| Roth Capital | maintain | Buy | Jun 18, 2025 |
| JMP Securities | maintain | Market Outperform | Jun 17, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jun 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 26, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 2, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 1, 2024 |
| Barclays | maintain | Equal Weight | Oct 23, 2023 |
| Barclays | downgrade | Overweight →Equal Weight | Sep 7, 2022 |
| Raymond James | downgrade | Strong Buy →Outperform | Sep 6, 2022 |
| BMO Capital | maintain | Outperform | Aug 11, 2022 |
| Raymond James | maintain | Strong Buy | Feb 11, 2022 |
| JMP Securities | maintain | Market Outperform →Outperform | Sep 14, 2021 |
| Cantor Fitzgerald | maintain | Overweight | Jul 30, 2021 |
| Alliance Global Partners | maintain | Buy | Aug 10, 2020 |
| Barclays | maintain | Overweight | Jul 21, 2020 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $0.46| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.35 | $-0.38 | — | $300.0K |
| May 13, 2026 | $-0.35 | $-0.47 | — | — |
| Feb 11, 2026 | $-0.41 | $-0.34 | — | — |
| Nov 12, 2025 | $-0.37 | $-0.54 | — | — |
| Aug 13, 2025 | $-0.78 | $-0.53 | — | — |
| May 14, 2025 | $-0.70 | $-0.80 | — | — |
| Feb 12, 2025 | $-1.13 | $-0.90 | — | — |
| Nov 13, 2024 | $-1.22 | $-1.07 | — | — |
News
PolyPid Ltd. is rated BUY with a $7.25 price target, offering 35% upside ahead of the November 28, 2026 FDA decision on D-PLEX100. SHIELD II Phase 3 data showed clinically meaningful reductions in surgical site infections, but prior SHIELD I failure and regulatory risks temper conviction. The Azurity partnership secures commercialization in the U.S. and Canada, with $320 million in potential milestone payments and mid-teens-to-mid-20s royalty rates.
PolyPid Ltd. (PYPD) Analyst/Investor Day Transcript
PETACH TIKVA, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its third quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 11, 2026.
PolyPid NASDAQ: PYPD outlined plans to expand its commercial and development strategy through 2030 at an investor day, as the company approaches a November 28, 2026, FDA action date for its D-PLEX100 surgical-site infection prevention product candidate.
Company to host virtual Investor Day today at 11:30 AM ET, featuring key opinion leader Warren S. Joseph, DPM, FIDSA All scheduled FDA interactions on track and aligned with D-PLEX ₁₀₀ November 28, 2026 PDUFA goal date PolyPid introduces PD01B, a new product candidate targeting hyper-localized, controlled-release antibiotic treatment of diabetic foot infections, based on the Company's proprietary Kynatrix technology PD01B planned to be developed as a new NDA; pre-IND meeting and first-in-huma…
Analysis demonstrates a lower bacterial burden in breakthrough surgical-site infections, with similar proportions of multidrug-resistant organisms between treatment groups Analysis demonstrates a lower bacterial burden in breakthrough surgical-site infections, with similar proportions of multidrug-resistant organisms between treatment groups
Management to outline ‘PolyPid 2030', the Company's long-term vision and pipeline strategy Event to feature Warren S. Joseph, DPM, FIDSA, a nationally recognized specialist in lower extremity infectious diseases Petach Tikva, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd.
PolyPid (NASDAQ: PYPD) is approaching a November 28 PDUFA date for D-PLEX100, its lead product candidate for preventing surgical site infections in patients undergoing colorectal surgery, Chief Executive Officer Dikla Czaczkes Akselbrad said during the Lytham Partners Fall 2026 Investor Conference. The company submitted its New Drug Application earlier this year, and the FDA accepted the
PolyPid NASDAQ: PYPD is approaching a November 28 PDUFA date for D-PLEX100, its lead product candidate for preventing surgical site infections in patients undergoing colorectal surgery, Chief Executive Officer Dikla Czaczkes Akselbrad said during the Lytham Partners Fall 2026 Investor Conference.
PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month
PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that PolyPid and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe.
PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in the following upcoming investor conferences:
PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript
PolyPid NASDAQ: PYPD said its second-quarter 2026 was marked by the FDA's acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada.
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance